Emanuele Pontali
Overview
Explore the profile of Emanuele Pontali including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
103
Citations
1647
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Baiardi G, Cameran Caviglia M, Boni S, Di Paolo A, Marini V, Cangemi G, et al.
Antibiotics (Basel)
. 2025 Feb;
14(2).
PMID: 40001433
Dalbavancin (DAL) is a long-acting lipoglycopeptide active against Gram-positive bacteria, including multidrug-resistant isolates. A growing body of evidence supports its efficacy in various difficult-to-treat infections. DAL shows time-dependent bactericidal activity...
2.
Pontali E, Baiardi G, Del Puente F, Mattioli F
Antibiotics (Basel)
. 2025 Feb;
14(2).
PMID: 40001408
Currently, two long-acting antibiotics are available: oritavancin (ORI) and dalbavancin (DBV) [...].
3.
Porretto M, Parente F, Del Puente F, Parisini A, Tigano S, Nelli M, et al.
J Prev Med Hyg
. 2024 Oct;
65(2):E273-E277.
PMID: 39431001
Introduction: Surgical site infections (SSIs) are among the most frequently encountered complications in prosthetic surgery, and are associated with increased hospitalization, costs and in-hospital mortality. There is no national system...
4.
Giacobbe D, Labate L, Russo Artimagnella C, Marelli C, Signori A, Di Pilato V, et al.
Infect Dis Ther
. 2024 Jul;
13(9):1929-1948.
PMID: 38995601
Introduction: Cefiderocol is a siderophore cephalosporin showing activity against various carbapenem-resistant Gram-negative bacteria (CR-GNB). No data currently exist about real-world use of cefiderocol in terms of types of therapy (e.g.,...
5.
Boccardi D, Marini V, Baiardi G, Cameran Caviglia M, Sacco F, Piras F, et al.
Clin Chim Acta
. 2024 Jun;
561:119806.
PMID: 38852792
Background And Aims: Ceftobiprole is a recent 5 generation parenteral cephalosporin with antibacterial activity against a large range Gram+ and Gram- bacteria. Therapeutic drug monitoring (TDM) is an essential tool...
6.
Corti N, Menzaghi B, Orofino G, Guastavigna M, Lagi F, Di Biagio A, et al.
Viruses
. 2024 Apr;
16(4).
PMID: 38675955
Cardiovascular disease (CVD) is common in people with HIV (PWH), and has great impact in terms of morbidity and mortality. Several intertwined mechanisms are believed to play a role in...
7.
Bartalucci C, Baldi F, Ricci E, Orofino G, Menzaghi B, Ferrara S, et al.
AIDS
. 2024 Feb;
38(3):430-434.
PMID: 38300162
Injectable cabotegravir and rilpivirine long-acting therapy is a revolutionary new antiretroviral treatment (ART) option for HIV infection in virologically suppressed adults on a stable ART. The aim of this study...
8.
Boni S, Sartini M, Del Puente F, Adriano G, Blasi Vacca E, Bobbio N, et al.
J Clin Med
. 2024 Jan;
13(2).
PMID: 38256530
In several settings, the COVID-19 pandemic determined a negative impact on the occurrence of healthcare-associated infection, particularly for on central lines associated bloodstream infections (CLABSI). In our setting, we observed...
9.
Fiore V, De Vito A, Rastrelli E, Manca V, De Matteis G, Ranieri R, et al.
Viruses
. 2023 Dec;
15(12).
PMID: 38140655
Background: Women represent less than 5% of the incarcerated population in Italy, with very limited data on HCV infection. Higher HCV seroprevalence and active infection rates have been described among...
10.
Baiardi G, Cameran Caviglia M, Piras F, Sacco F, Prinapori R, Cristina M, et al.
Antibiotics (Basel)
. 2023 Oct;
12(10).
PMID: 37887199
Oritavancin (ORI) is a semisynthetic lipoglycopeptide approved as a single 1200 mg dose intravenous infusion for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) caused by Gram-positive...